A CDK4/6 inhibitor, such as palbociclib, demonstrated its efficacy in patients with treatment‐naive HR+/HER2− breast cancer experiencing visceral metastases [2], but those having visceral crises or aggressive visceral metastasis were excluded from the trial. This evidence concerns the gene CDK4 and breast carcinoma.